China’s Regulatory System Enters a New Phase of Modernization China’s pharmaceutical regulatory system is entering a new phase of accelerated modernization, creating policy driven opportunities for innovative drug development and global collaboration. The Fourth Revision of the Regulations for the Implementation of the Drug Administration Law , issued by the State Council in January 2026 and scheduled to take effect on May 15, 2026, represents the most structurally significant update in over two